Amgen Inc. (AMGN) Stake Held by Pictet North America Advisors SA
Pictet North America Advisors SA held its position in shares of Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,944 shares of the medical research company’s stock at the end of the 2nd quarter. Pictet North America Advisors SA’s holdings in Amgen were worth $335,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. PGGM Investments boosted its holdings in shares of Amgen by 2.3% during the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after purchasing an additional 15,059 shares during the period. Shelton Capital Management boosted its holdings in shares of Amgen by 82.7% during the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after purchasing an additional 49,354 shares during the period. Greylin Investment Mangement Inc. boosted its holdings in shares of Amgen by 466.9% during the second quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock worth $2,416,000 after purchasing an additional 11,555 shares during the period. Kelman Lazarov Inc. boosted its holdings in shares of Amgen by 8.2% during the second quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock worth $272,000 after purchasing an additional 120 shares during the period. Finally, Osborne Partners Capital Management LLC boosted its holdings in shares of Amgen by 0.5% during the second quarter. Osborne Partners Capital Management LLC now owns 17,023 shares of the medical research company’s stock worth $2,932,000 after purchasing an additional 91 shares during the period. Institutional investors and hedge funds own 78.15% of the company’s stock.
In related news, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $171.58, for a total transaction of $261,659.50. Following the sale, the executive vice president now directly owns 57,631 shares of the company’s stock, valued at approximately $9,888,326.98. The disclosure for this sale can be found here. Insiders have sold 7,050 shares of company stock valued at $1,239,673 in the last three months. 0.19% of the stock is owned by insiders.
Shares of Amgen Inc. (AMGN) opened at $169.84 on Wednesday. The firm has a market cap of $122,526.45, a P/E ratio of 13.42, a P/E/G ratio of 2.45 and a beta of 1.37. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. Amgen Inc. has a 1 year low of $138.83 and a 1 year high of $191.10.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm’s quarterly revenue was down .7% compared to the same quarter last year. During the same quarter last year, the firm earned $3.02 earnings per share. research analysts forecast that Amgen Inc. will post 12.66 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a dividend yield of 2.71%. The ex-dividend date is Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is currently 41.63%.
Amgen announced that its Board of Directors has authorized a stock buyback plan on Wednesday, October 25th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.
A number of research firms have recently weighed in on AMGN. Argus lowered shares of Amgen from a “buy” rating to a “hold” rating and increased their target price for the stock from $175.22 to $195.00 in a report on Wednesday, November 1st. Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Mizuho set a $198.00 target price on shares of Amgen and gave the stock a “buy” rating in a report on Sunday, October 29th. BMO Capital Markets reiterated a “market perform” rating and set a $198.00 target price on shares of Amgen in a report on Thursday, October 26th. Finally, Morgan Stanley dropped their target price on shares of Amgen from $196.00 to $193.00 and set an “overweight” rating for the company in a report on Thursday, October 26th. Thirteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Amgen has an average rating of “Buy” and an average price target of $190.03.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.